Daily non-political popular news in brief.

Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis

One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.

Read more »

Keywords: ustekinumab, phase, data, show, long-term, improvement, chronic, plaque, psoriasis, long, term, psoriasi

« Previous | Next »

Similar news on "Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis":

1. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
   10-03-2007 · EurekAlert!
   The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index.
   Similar news · Read more »
   
2. Survey indicates people with chronic moderate to severe plaque psoriasis may be undertreated
   02-02-2007 · EurekAlert!
   The National Psoriasis Foundation and Amgen today released data, which show that nearly 40 percent of patients with chronic moderate to severe psoriasis are not currently receiving any treatment. Further, more than half of moderate to severe patients on treatment are not being treated in accordance with AAD guidelines, which state that patients diagnosed with chronic moderate to severe plaque psoriasis are candidates for phototherapy or systemic therapy, including biologic agents.
   Similar news · Read more »
   
3. Long-term ulcerative colitis study shows Remicade responders maintained improvement
   05-23-2007 · EurekAlert!
   Findings presented today at Digestive Disease Week 2007, from long-term extensions of the ACT trials show that subjects with moderately to severely active ulcerative colitis who had responded to REMICADE in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.
   Similar news · Read more »
   
4. 1-year results of bronchial thermoplasty in refractory asthma
   02-11-2008 · EurekAlert!
   Data from the Research in Severe Asthma trial of bronchial thermoplasty published in the American Journal of Respiratory and Critical Care Medicine show that patients experienced long term improvement in pulmonary function, improved quality of life and asthma control, and a reduction in rescue medication use for patients treated with bronchial thermoplasty.
   Similar news · Read more »
   
5. New analyses reinforce efficacy of Remicade in treatment of severe psoriasis
   02-02-2007 · EurekAlert!
   Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving Remicade (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (PASI 75).
   Similar news · Read more »
   
6. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
   09-10-2007 · EurekAlert!
   Accentia Biopharmaceuticals announces evidence that most, if not all cases of chronic sinusitis, are due to a fungal-induced inflammation as originally proposed by investigators at the Mayo Clinic. The data were collected as part of the company's ongoing pivotal phase 3 clinical trial for its lead pharmaceutical product, SinuNase™, an intranasal formulation of the antifungal amphotericin B 0.01 percent suspension.
   Similar news · Read more »
   
7. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
   05-23-2007 · EurekAlert!
   Shire plc today announced that VYVANSE effectively controlled ADHD symptoms in children aged 6 to 12 years. In addition, 95 percent of children taking VYVANSE daily for 12 months showed overall improvement, according to phase 3 open-label extension trial results. Further analysis of phase 2 clinical data demonstrated that VYVANSE provided consistent time to maximum concentration of d-amphetamine from patient to patient. Both studies were presented at the annual meeting of the American Psychiatric Association.
   Similar news · Read more »
   
8. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
   10-23-2006 · EurekAlert!
   Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
   Similar news · Read more »
   
9. Fosrenol data show evidence of trends towards improved bone formation in CKD stage 5 patients
   11-17-2006 · EurekAlert!
   Treatment with the phosphate binder Fosrenol, lanthanum carbonate, was associated with slight improvements in bone formation in chronic kidney disease stage 5 patients with high phosphorus levels in the blood, according to long-term data presented at the American Society of Nephrology meeting. Additional studies presented at ASN document the efficacy and safety of the reformulated and higher-dose FOSRENOL tablets. Of the approximately 20 million Americans who have some form of kidney disease, more than 530,000 have developed CKD Stage 5.
   Similar news · Read more »
   
10. Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation
    06-15-2007 · EurekAlert!
    Data presented today at the European League Against Rheumatism Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis who received Remicade over two years experienced significant improvement in spinal mobility. In addition, Remicade-treated patients showed sustained reductions in spinal inflammation through two years as detected by magnetic resonance imaging.
    Similar news · Read more »